Marshall Wace, LLP Terns Pharmaceuticals, Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 803,336 shares of TERN stock, worth $2.96 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
803,336
Previous 104,758
666.85%
Holding current value
$2.96 Million
Previous $873,000
413.4%
% of portfolio
0.01%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding TERN
# of Institutions
160Shares Held
83.9MCall Options Held
473KPut Options Held
119K-
Soleus Capital Management, L.P. Greenwich, CT8.14MShares$30 Million3.16% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$27.9 Million1.14% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$25.4 Million7.51% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.58MShares$20.6 Million1.37% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY4.75MShares$17.5 Million0.17% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $139M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...